Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	38.97B +156.1%
Revenue (ttm)	7.42B +16.5%
Net Income	920.34M +0.8%
EPS	1.68 +0.0%
Shares Out	543.49M
PE Ratio	42.67
Forward PE	25.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,745,354
Average Volume	790,319
Open	66.60
Previous Close	66.00
Day's Range	66.10 - 72.45
52-Week Range	23.00 - 92.00
Beta	0.59
RSI	61.33
Earnings Date	Mar 20, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,537
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY